EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia

Haematologica

Volumn 99, Issue 11, 2014, Pages e225-e227

  Matsuo, Hidemasa ^a   Kajihara, Mio ^a   Tomizawa, Daisuke ^b   Watanabe, Tomoyuki ^c   Saito, Akiko Moriya ^d   Fujimoto, Junichiro ^e   Horibe, Keizo ^d   Kodama, Kumi ^a   Tokumasu, Mayu ^a   Itoh, Hiroshi ^a   Nakayama, Hideki ^f   Kinoshita, Akitoshi ^g   Taga, Takashi ^h   Tawa, Akio ⁱ   Taki, Tomohiko ^j   Shiba, Norio ^k   Ohki, Kentaro ^l   Hayashi, Yasuhide ^l   Yamashita, Yuka ^d   Shimada, Akira ^m   Tanaka, Shiro ^a   Adachi, Souichi ^a   more..

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^g ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

ⁱ OSAKA NATIONAL HOSPITAL   (Japan)

^j KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^k GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l Gumna Children S Medical Center   (Japan)

^m OKAYAMA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Acute myeloid leukemia; EVI1; MLL; Pediatrics; Prognostic factor

Indexed keywords

MIXED LINEAGE LEUKEMIA AF9 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MECOM PROTEIN, HUMAN; MLL PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CANCER RECURRENCE; CHILD; CHROMOSOME REARRANGEMENT; ECOTROPIC VIRAL INTEGRATION SITE-1 GENE; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; ACUTE MYELOBLASTIC LEUKEMIA; GENE TRANSLOCATION; GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE;

DNA-BINDING PROTEINS; GENE EXPRESSION; GENE REARRANGEMENT; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROGNOSIS; PROTO-ONCOGENES; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 84908459601     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.107128     Document Type: Letter

References (14)

1. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54(6):831-40.
2. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011;208(12):2403-16.
3. Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC et al. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. Br J Haematol. 2013;162(5):670-7.
4. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011;117(23):6304-14.
5. Barjesteh van, Waalwijk van, Doorn-Khosrovani S Erpelinck C Van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood. 2003; 101(3):837-45.
6. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329-37.
7. Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101-7.
8. Vázquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, et al. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica. 2011;96(10):1448-56.
9. Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol. 2013;31(1):95-103.
10. Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010; 24(5):942-9.
11. Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-96.
12. Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T et al. Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol. 2013;98(5):578-88.
13. Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV et al. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood. 2012;119(24):5838-49.
14. Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A et al. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Leukemia. 2011; 25(6):921-31.